Nucleic acid extraction market seen topping $8.78B by 2030

The global nucleic acid extraction instruments and reagents market is projected to grow from $4.97 billion in 2025 to $5.54 billion in 2026, with North America leading the market. The Business Research Company says rising molecular diagnostics, chronic disease testing and automation are driving demand toward $8.78 billion by 2030.

Why it matters: - Nucleic acid extraction tools sit at the front end of molecular diagnostics, genomics and research workflows. - Stronger demand for DNA and RNA isolation supports faster testing, broader automation and higher-throughput lab operations. - The market’s growth is tied to rising chronic disease testing and expanded use of precision medicine.

What happened: - The Business Research Company released a 2026 market report on nucleic acid extraction instruments and reagents. - The market is projected to rise from $4.97 billion in 2025 to $5.54 billion in 2026. - That implies 11.5% annual growth. - The market is forecast to reach $8.78 billion by 2030, at a 12.2% CAGR. - North America held the largest global market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Nucleic acid extraction instruments and reagents are used to isolate and purify DNA and RNA from biological samples. - The category includes specialized machines and chemical agents used across extraction steps. - The tools are used in molecular biology, genetics and diagnostic laboratories. - The market’s recent growth has been driven by more molecular diagnostics testing, wider use of PCR-based methods, expanding genomics and proteomics research, greater use of automated lab workflows and more ready-to-use extraction kits. - The company said future growth will be supported by personalized medicine, broader infectious disease testing, higher genomics investment, more fully automated laboratory systems and pressure for faster diagnostic turnaround times. - The report also highlights rising use of automated extraction technologies, magnetic bead-based methods, integrated sample-to-result platforms and a focus on accuracy and reproducibility. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Chronic non-communicable diseases are a major demand driver because they increase the need for molecular diagnostics, biomarker analysis, pharmacogenomics and disease monitoring. - The report cites American Heart Association data showing the US age-adjusted cardiovascular death rate rose to 233.3 per 100,000 people in 2024 from 224.4 in 2023. - That kind of disease burden helps explain why extraction systems are becoming more important in clinical and research settings. - The report’s added analytics, including TAM analysis, market attractiveness scoring and forecasting dashboards, signal a push toward more decision-ready market intelligence.

What's next: - The market is expected to keep expanding as labs automate more workflows and demand for rapid diagnostics grows. - Adoption of high-throughput extraction platforms and integrated sample-to-result systems should continue to shape product development. - More investment in genomics research and personalized medicine is likely to support longer-term demand.

The bottom line: - Nucleic acid extraction is shifting from a support function to a growth market of its own, with automation, diagnostics and chronic disease testing driving the next leg higher.